Cellectar Biosciences (FRA:NV4) Short-Term Capital Lease Obligation : €0.07 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences Short-Term Capital Lease Obligation?

Cellectar Biosciences's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.07 Mil.

Cellectar Biosciences's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (€0.05 Mil) to Dec. 2023 (€0.05 Mil) and increased from Dec. 2023 (€0.05 Mil) to Mar. 2024 (€0.07 Mil).

Cellectar Biosciences's annual Short-Term Capital Lease Obligation declined from Dec. 2021 (€0.12 Mil) to Dec. 2022 (€0.05 Mil) but then increased from Dec. 2022 (€0.05 Mil) to Dec. 2023 (€0.05 Mil).

Cellectar Biosciences Short-Term Capital Lease Obligation Historical Data

The historical data trend for Cellectar Biosciences's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Short-Term Capital Lease Obligation Chart

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.10

0.12

0.05

Cellectar Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.05	0.05	0.05	0.05	0.07

Cellectar Biosciences Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Cellectar Biosciences Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (FRA:NV4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CLRB:USA

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines